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A B S T R A C T
Background
Multifocal motor neuropathy (MMN) is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually
multiple partial motor nerve conduction blocks. Intravenous immunoglobulin (IVIg) is beneficial but the role of immunosuppressive
agents is uncertain. This is an update of a review first published in 2002 and previously updated in 2003, 2005, 2008 and 2011.
Objectives
To assess the effects of immunosuppressive agents for the treatment of multifocal motor neuropathy.
Search methods
On 22 September 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE,
EMBASE and LILACS for trials of MMN. We also searched two trials registers for ongoing studies.
Selection criteria
We planned to include randomised controlled trials (RCTs) and quasi-RCTs. We considered prospective and retrospective case series
and case reports in the Discussion.
Data collection and analysis
Two review authors searched the titles and abstracts of the articles identified and extracted the data independently.
Main results
Only one RCT of an immunosuppressive or immunomodulatory agent has been performed in MMN. This study randomised 28
participants and showed that mycophenolate mofetil, when used with IVIg, did not significantly improve strength, function or reduce
the need for IVIg. No serious adverse events were observed. The study was deemed at low risk of bias. We summarised the results of
retrospective and prospective case series in the discussion.
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Authors’ conclusions
According to moderate quality evidence, mycophenolate mofetil did not produce significant benefit in terms of reducing need for IVIg
or improving muscle strength in MMN. Trials of other immunosuppressants should be undertaken.
P L A I N L A N G U A G E S U M M A R Y
Treatments that suppress or modify the immune system for multifocal motor neuropathy
Review question
We reviewed the evidence for the benefits and harms of treatments that suppress or modify the immune system in multifocal motor
neuropathy (MMN).
Background
MMN is a rare condition causing progressive weakness of the limbs, especially the hands and arms. This disorder is believed to be driven
by an immune-based process. The usual treatment is infusion of immunoglobulin (antibodies purified from the blood) into a vein
(IVIg). This is expensive, needs to be repeated every few weeks and is not always completely effective. Immunosuppressive drugs (drugs
that suppress immune responses) such as cyclophosphamide, azathioprine, ciclosporin, interferon beta-1a, mycophenolate mofetil and
rituximab have been tried as initial or add-on treatments.
Study characteristics
We found only one randomised controlled trial (RCT), of a drug called mycophenolate mofetil. The trial involved 28 people with
MMN.
Key results and quality of the evidence
The trial provided moderate quality evidence that mycophenolate mofetil, when used with IVIg, did not reduce the requirement for
IVIg or improve muscle strength of trial participants with MMN. No serious side-effects were observed. The risk of bias was low in
this study. New RCTs of other immunosuppressive drugs are needed to identify beneficial treatments for MMN.
The evidence is current to September 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mycophenolate mofetil versus placebo for multifocal motor neuropathy
Patient or population: people with multifocal motor neuropathy
Settings: single centre outpatient clinic
Intervention: mycophenolate mofetil versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Mycophenolate mofetil
Improvement in GNDS
after 12 months1
143 per 10002 77 per 1000
(9 to 752)
RR 0.54
(0.06 to 5.26)
28
(1 study)
⊕⊕⊕©
moderate3
Not significant. Primary
outcome of the authors,
50% reduction of IVIg
dose, achieved by 1
mycophenolate and 0
placebo participants, also
not significant
Serious adverse events See comment See comment Not estimable 28
(1 study)
⊕⊕⊕©
moderate3
No serious adverse
events. Headache oc-
curred in 7 out of 14 my-
cophenolate and 1 out of
14 placebo participants,
almost statistically signif-
icant
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI)
CI: confidence interval; RR: risk ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate
1 GNDS is Guy’s Neurological Disability Score, which ranks functional impairment from normal function, zero to impossible to use arm
or leg, five. A single grade change would be noticeable by a person with MMN.
2 Assumed risk is that of the placebo group in the included study.
3 Only one trial with 28 participants .
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Multifocal motor neuropathy (MMN) is a distinct clinical entity
characterised by progressive, predominantly distal, asymmetrical
limb weakness and minimal sensory complaints (Bouche 1995;
Chad 1986; ENMC 2001; Krarup 1990; Nobile-Orazio 2001).
Cranial and proximal limb muscles are usually spared. The up-
per limbs, particularly the hands, are more commonly involved
than the lower limbs. The diagnostic hallmark of MMN is the
presence of multiple motor nerve conduction blocks which are re-
quired by the American Association of ElectrodiagnosticMedicine
(AAEEM) and Peripheral Nerve Society (PNS) consensus criteria
(Olney 2003; van Schaik 2006), although a similar clinical syn-
drome may occur in the absence of such blocks (Chaudhry 2006;
Delmont 2006; Slee 2007). MMN is most likely immune-medi-
ated. It shares some characteristics with chronic inflammatory de-
myelinating polyradiculoneuropathy and the Lewis-Sumner syn-
drome or multifocal acquired demyelinating sensory and motor
neuropathy with persistent conduction block (MADSAM), but is
probably a distinct entity (Gorson 1999; Lewis 1982; Lewis 1999;
Saperstein 1999; Viala 2004).
In a longitudinal study of 46 people with MMN, followed for
a median of 2.3 years, spontaneous improvement or resolution
did not occur (Taylor 2000). Repeated administration of intra-
venous immunoglobulin (IVIg) has become standard treatment
for MMN. Various case-reports and small randomised studies
supported this practice (Azulay 1994; Charles 1992; Chaudhry
1993; Comi 1994; Cruz 1993; Hoang-Xuan 1993; Léger 1994;
Nobile-Orazio 1993; van den Berg 1995; Yuki 1993) Two ran-
domised trials, one with 16 (Federico 2000) and another with 19
(Léger 2001) participants, have confirmed the efficacy of IVIg in
MMN. A Cochrane systematic review on the treatment of MMN
concluded that IVIg produces significant short-term improvement
in strength (van Schaik 2005).
Some people with MMN experience progression of neurological
deficits in spite of intensive therapy with IVIg. In a longitudinal
study (van den Berg 1998), significant deterioration of strength
occurred in some muscle groups, even in participants who were
receiving IVIg as often as once weekly. van den Berg-Vos 2002
and Terenghi 2004 also showed that long-term treatment with
IVIg may not prevent the reduction of the amplitude of the distal
compound muscle action potential which may represent axonal
loss.More sustained responses have been reportedwith larger doses
of IVIg. Vucic 2004 treated 10 participants initially with 2 g/kg
of IVIg monthly for three months. This was followed by four-
weekly infusions of IVIg, the dose of which was gradually adjusted
so that no functional decline occurred before the next treatment.
Changes in IVIg dose were made in steps of 0.4 g/kg every fourth
week. There was significant and sustained improvement of muscle
strength and functional disability in all participants through this
period of treatment (range, 3.5 to 12 years). Slee 2007 also reported
sustained improvement comparedwith baselinewith a comparable
high dose regimen, although gains were not always sustained. A
recent study of 88 people with MMN showed that early treatment
with IVIg can help reduce permanent deficits from axonal injury
(Cats 2010). However, some people with MMN do not respond
to IVIg at the outset or require progressively more frequent doses
to maintain remission (Azulay 1997; ENMC 2001). For example,
in a retrospective study of 40 people with MMN, six out of 20
treatment-naïve individuals did not respond to IVIg at sixmonths,
only eight of the 40 participants (22%) had significant remission
at six months, and 25 (68%) were dependent on periodic IVIg
infusions (Léger 2008). In Slee 2007, five of 24 people in whom
IVIg was tried did not respond.
Description of the intervention
The inadequate response, high cost and variable availability of IVIg
prompted the search for adjunctive immunosuppressive therapies.
Cyclophosphamide was the first to be used and was reported to be
beneficial when used on its own (Pestronk 1988) or as an adjunc-
tive treatment (Azulay 1997; Meucci 1997). However, cyclophos-
phamide and other immunosuppressive agents are associated with
potentially serious adverse effects. Their use in a relatively benign
disease such as MMN requires good evidence for efficacy.
Why it is important to do this review
When this review was first published in 2002 and then updated
in 2004, there were no randomised trials. In 2006, based on non-
randomised studies, a consensus group expressed the opinion that
immunosuppressive or immunomodulatory drugs such as cyclo-
phosphamide, ciclosporin, azathioprine, interferon beta-1a or rit-
uximab might be considered if IVIg was not sufficiently effective
(van Schaik 2006). In 2007, a high quality trial of mycophenolate
mofetil was published and we updated this review to include it
in 2008. Mycophenolate mofetil inhibits T and B lymphocytes
by blocking purine synthesis. It has been used to prevent rejec-
tion of renal transplants and has low organ toxicity and potential
to cause mutations (Allison 2000; Halloran 1997). The possible
role of mycophenolate mofetil in the management of myasthe-
nia gravis, myositis and dysimmune neuropathies has been stud-
ied (Chaudhry 2001; Ciafaloni 2001;Meriggioli 2003;Mowzoon
2001; Pisoni 2007; Radziwill 2006; Sanders 2008). No further
trials were identified at the last update in 2011.
O B J E C T I V E S
Toassess the effects of immunosuppressive agents for the treatment
of multifocal motor neuropathy.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered for inclusion all randomised controlled trials
(RCTs). We also considered quasi-RCTs in which allocation was
not random but was intended to be unbiased (e.g. alternate allo-
cation). There were no restrictions as to language of publication.
We considered case series in the Discussion only.
Types of participants
Since there is no specific diagnostic test for multifocal motor neu-
ropathy (MMN), precise case definition is crucial. According to
the guidelines set by the European Federation of Neurological So-
cieties/Peripheral Nerve Society (van Schaik 2006), we scrutinised
the following aspects of diagnosis in the reports of people with
MMN.
Conduction block in nerve conduction tests
The diagnostic hallmark of MMN is persistent partial motor con-
duction block, a reduction in the compound muscle action po-
tential (CMAP) amplitude and area after proximal as compared to
distal stimulation, at sites not prone to compression (Cornblath
1991;Rhee1990). There is nouniversal agreement onwhat consti-
tutes pathological conduction block in clinical studies. Computer
simulation models of rat individual motor unit action potentials
(MUAP) have demonstrated that the phenomenon of temporal
dispersion with interphase cancellation can reduce the CMAP area
by up to 50% and the amplitude by even more (Rhee 1990). This
model has been applied to the forearm segment of the median
nerve in humans. It shows that the criteria for conduction block,
at least in this nerve segment, may depend not only on the pro-
longation of the CMAP duration on proximal versus distal stimu-
lation, but also on the absolute duration of the distal CMAP (van
Asseldonk 2006). Nevertheless, many investigators have accepted
a decrease in the CMAP amplitude of more than 50% from distal
to proximal sites of stimulation, associated with a less than 15%
increase in negative peak duration, as the criterion for patholog-
ical conduction block. A reduction in CMAP area of more than
50% has also been suggested as the criterion (ENMC 2001; van
Es 1997). Short segment evaluation of nerves (2 cm to 4 cm)
may allow easier differentiation of conduction block (where there
would be an abrupt change in area or amplitude) from temporal
dispersion (where the change is gradual) (Cornblath 1991).
With less stringent electrodiagnostic criteria, some believe that
there is a risk of including non-MMN cases (ENMC 2001; van
Es 1997). However, there is also evidence that otherwise typical
MMN may present without overt conduction block (Chaudhry
2006; Delmont 2006; Nobile-Orazio 2002; Pakiam 1998; Slee
2007). For the purpose of this review, we accepted the various
diagnostic criteria used by authors of studies provided that they
conformed to the spirit of the criteria recently proposed (ENMC
2001; Olney 2003; van Schaik 2006).
Sensory abnormalities
Sensory nerve pathology has been reported in MMN (Corse
1996). However, sensory symptoms and signs, if present, are not
prominent. By contrast ’multifocal demyelinating sensorimotor
neuropathy with persistent conduction block’ also known as the
Lewis-Sumner syndrome has prominent sensory features (Lewis
1982). There is some controversy about whether this condition is
distinct or is part of the spectrum of MMN (Lewis 1999; Mezaki
1999; Oh 1997; Oh 2000; Saperstein 1999; van den Berg-Vos
2000a; Viala 2004). However, in order to focus on a homoge-
neous clinical entity, this review excluded people withMMNwith
prominent sensory symptoms or signs.
Ganglioside antibodies
Antibodies to gangliosideGM1have been reported in 20% (Lange
1992; Taylor 1996) to 80% (Kornberg 1994; Pestronk 1990) of
people with MMN. In view of the wide variability in their oc-
currence, and the difference in assay performance between labo-
ratories (Nobile-Orazio 2001; Willison 1999) we did not use the
presence of GM1 antibodies as a diagnostic criterion.
Types of interventions
Treatment with immunosuppressive or immunomodulatory
agents, including corticosteroids and plasma exchange but not
IVIg. The intervention might have been used alone or in com-
bination with IVIg and compared with placebo, no treatment or
another treatment.
Types of outcome measures
Primary outcomes
Significant improvement at least six months after randomisation.
We considered significant improvement to have occurred if a par-
ticipant improved by one or more points on the modified Rankin
disability scale (van Swieten 1988). This scale has the following
grades:
0: asymptomatic;
1: non-disabling symptoms not interfering with lifestyle;
2: minor disability symptoms leading to some restriction of
lifestyle but not interfering with the person’s capacity to look after
themselves;
3: moderate disability symptoms significantly interfering with
lifestyle or preventing fully independent existence;
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4: moderately severe disability symptoms preventing independent
existence although people do not need constant attention day and
night;
5: totally dependent, requiring constant attention day and night.
We would have converted any other similar disability scales (for
example a functional scale for upper and lower limbs (Nobile-
Orazio 1993)) so that a one point change would have been similar
to the modified Rankin scale.
Secondary outcomes
1. Significant improvement at least six months after
randomisation on impairment scales such as the Medical
Research Council (MRC) sum score (Kleyweg 1991) or grip
strength. The MRC score rates each muscle group from zero =
no movement to five = full power. The MRC sum score is the
sum of the scores of six upper and six lower limb muscle groups
giving a maximum of 60. We would have considered a change of
at least one point in the MRC score to be significant in studies
evaluating improvement in a single muscle, and a change of at
least five per cent in the MRC sum score in studies evaluating
improvement in several muscles.
2. Requirement for IVIg treatment before and after at least six
months of treatment with immunosuppressive agents, calculated
as the cumulative dose in g/kg/month and compared between
the treated and control groups.
3. Improvement in motor conduction block after at least six
months; defined as either resolution of conduction block (as
described above) or statistically significant improvement in the
degree of partial conduction block in the nerves studied.
Previous studies have reported variable correlation between
improvement of conduction block and clinical response to
treatment (Federico 2000; Léger 2001; Léger 2008).
4. Serious adverse events attributable to the use of
immunosuppressive agents. We defined serious adverse events as
any event that:
i) was fatal;
ii) was life threatening (places the person at immediate
risk of death);
iii) required or prolonged hospitalisation;
iv) was severely or permanently disabling; or
v) resulted in the development of a malignancy
Search methods for identification of studies
We revised the search strategies for this update for all databases.
We searched the Cochrane Neuromuscular Disease Group Spe-
cialized Register (22 September 2014), CENTRAL (2014, Issue 7
in The Cochrane Library), MEDLINE (January 1966 to Septem-
ber 2014), EMBASE (January 1980 to September 2014) and
LILACS (January 1982 to September 2014) on 22 September
2014. MMN has only been recognised as a clinical entity since
the late 1980s (Chad 1986; Krarup 1990; Parry 1985; Pestronk
1988; Roth 1986). To avoid missing earlier reports without the
diagnostic label of MMN, we also used the keywords ’conduction
block’ and ’motor neuropathy’ for the search.
Electronic searches
The revised search strategies are detailed in Appendix 1 (Cochrane
Neuromuscular Disease Group Specialized Register), Appendix 2
(CENTRAL), Appendix 3 (MEDLINE), Appendix 4 (EMBASE)
and Appendix 5 (LILACS).
Searching other resources
We searched ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization Clinical Trials Registry Platorm (IC-
TRP) (www.who.int/ictrp/en/) for ongoing trials on 3 January
2015. Additionally, we checked references in papers on MMN to
identify any additional published or unpublished data.
Data collection and analysis
Selection of studies
Two authors independently scrutinised the full text of all relevant
identified studies and selected trials that fitted the inclusion crite-
ria. If there had been any disagreements, we would have resolved
them by discussion and consultation with the other review au-
thors.
Data extraction and management
Two authors performed data extraction independently using a spe-
cially designed form.We collected data on trial design, participant
characteristics, outcomes, interventions and comparators, meth-
ods (including risk of bias), results, funding sources and conflicts
of interest among main investigators. We would have contacted
authors of studies formissing information if necessary.We checked
data and entered them into the computer twice to minimise tran-
scription errors.We would have resolved any disagreement by con-
sultation among the review authors.
Assessment of risk of bias in included studies
Following the guidance inThe Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), we completed a ’Risk of
bias’ table, addressing the followingdomains: sequence generation,
allocation concealment, blinding of participants and personnel,
blinding of outcome assessors, incomplete outcome data, selective
outcome reporting and other issues. We made a judgement about
the risk of bias for each entry, of “Low risk of bias”, “High risk
of bias” or “Unclear risk of bias”. We would have resolved any
disagreement by discussion among the review authors.
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Measures of treatment effect
We reported risk ratios (RRs) or risk differences (RDs), with 95%
confidence intervals (CIs), for dichotomous outcomes. For con-
tinuous outcomes we derived mean differences (MDs) and 95%
CIs.
Unit of analysis issues
There were no unit of analysis issues. We would have dealt with
these according to the guidance in The Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
If more than one study had been available and the results had been
heterogeneous (I² statistic > 40% (Higgins 2003), we would have
performed sensitivity analyses on the basis of individual aspects of
risk of bias. We would have conducted subgroup analyses for each
immunosuppressive agent.
Data synthesis
We would have calculated a treatment effect across the trials using
the Cochrane statistical package Review Manager 5 (RevMan)
(RevMan 2014) if more than one study had been available. If there
had been no heterogeneity,
we would have used a fixed-effect model and performed a sensitiv-
ity analysiswith a random-effectsmodel according toThe Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
’Summary of findings’ table
We created a ’Summary of findings’ table for the following out-
comes.
1. Improvement in neurological disability score after 12
months.
2. Serious adverse events.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of a body of evidence (studies that contribute
data for the prespecified outcomes). We used methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) using GRADEpro software (GRADEpro 2014). We justi-
fied all decisions to down- or up-grade the quality of studies using
footnotes and we made comments to aid reader’s understanding
of the review where necessary.
Subgroup analysis and investigation of heterogeneity
If more than one study had been available and the results had
been heterogeneous, we would have performed sensitivity analyses
on the basis of individual aspects of risk of bias. We would have
conducted subgroup analyses for each immunosuppressive agent.
R E S U L T S
Description of studies
Results of the search
In the previous versions of this review only one studymet the selec-
tion criteria. For this update the numbers of new papers found by
the revised strategies were 73 inMEDLINE, 58 in EMBASE, none
in LILACS, six in the Cochrane Neuromuscular Disease Group
Specialized Register and three in CENTRAL. After deduplication
there were 105 references but none met the inclusion criteria for
the review. We identified no potentially eligible ongoing trials in
clinical trials registers.
Included studies
The one previously included trial (see Characteristics of included
studies) was a randomised, single-centre, placebo-controlled, ’add-
on’ study of mycophenolate mofetil 1 g twice daily for one year
(Piepers 2007). Randomisation was stratified for the extent of
weakness at baseline. This was to ensure that the baseline strength
for both the treatment and placebo groups was similar. Three
months later intravenous immunoglobulin (IVIg) dose was re-
duced until a decline in muscle strength and functional status
was observed. The primary endpoint was 50% or more reduc-
tion of meanweekly IVIg dose. Secondary outcomemeasures were
improvement of muscle strength and functional status at three
months, and a reduction of immunoglobulin M (IgM) GM1 an-
tibody titre after 12 months of treatment. Muscle strength was
assessed using a modified Medical Research Council (MRC) sum
score of 15 muscles on both sides, making the maximum score
150. Grip strength and strength of weak muscles was quantified
using a hand-held dynamometer. Functional assessment was per-
formed using: (1) Guy’s Neurological Disability Scale (Sharrack
1999), which rates limbs from zero = normal functioning to five
= impossible to use the limb; (2) the self evaluation scale (Léger
2001), which scores five daily motor activities that are selected
by the participant and the physician at baseline, zero indicating
normal functioning and five impossible to perform activity; and
(3) the nine-hole peg test (Oxford 2003; Sharrack 1999).
The participants were receiving regular IVIg every two to five
weeks. IVIg was reduced 5 g per administration if the weekly dose
equalled or exceeded 15 g/week and 2.5 g per administration if
the weekly dose was lower than 15 g/week. This reduction was
discontinued if: (a) at least a one-point reduction was observed
on the Guy’s Neurological Disability Scale, or an increase of one
point on at least two items on the self evaluation scale; or (b)
dynamometry showed a 50% decline in muscle strength in at
least two clinically affected muscles; or (c) participants reported
an unacceptable decline in daily functioning. In such a case, IVIg
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was increased and when the participant was stable again another
reduction was attempted. If the participant deteriorated again,
IVIg dose reduction was abandoned.
Twenty-eight participants were randomised from an initial cohort
of 65 participants that were considered. Twenty-four of the 28 par-
ticipants satisfied criteria for definite multifocal motor neuropathy
(MMN), three for probable MMN and one for possible MMN.
One participant that was initially enrolled was excluded from ran-
domisation because of large fluctuations in muscle strength. The
baseline characteristics, in particular the mean duration of IVIg
maintenance treatment,mean IVIg dose per week,muscle strength
and functional scores were similar between the mycophenolate
mofetil treated and placebo groups. Two participants withdrew
from the study after three months, one was taking mycopheno-
late mofetil and complained of flu-like symptoms. The other was
on placebo and was deteriorating rapidly. These subjects were in-
cluded so an intention-to-treat analysis was performed. None was
lost to follow-up.
In the absence of RCTs of other agents, we have summarised the
observational studies in the Discussion.
Risk of bias in included studies
The one included study (Piepers 2007) had a low risk of bias, hav-
ing adequate allocation concealment, comparison of experimen-
tal groups, explicit diagnostic criteria, completeness of follow-up,
blind outcome assessment and blind administration of treatment
(Figure 1, Characteristics of included studies). Intention-to-treat
analysis was performed. No participant was lost to follow-up. The
small size of the trial reduced the grading of evidence quality in
Summary of findings for themain comparison tomoderate. How-
ever, in this rare disease, recruiting so many participants was a re-
markable achievement.
Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. Green (+) = low risk of bias.
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Effects of interventions
See: Summary of findings for the main comparison
Mycophenolate mofetil versus placebo for multifocal motor
neuropathy
The only RCT tested mycophenolate mofetil. We report in this
section first the outcomes selected in the protocol for this review
and then the other outcomes reported by the authors of the trial.
Primary outcome measure
Significant improvement at least six months after
randomisation
Scores for the Rankin scale were not available but the authors re-
ported the mean (SD) scores for the Guy’s Neurological Disability
Scale (Sharrack 1999) at 3, 6 and 12 months. This measurement
in this trial was difficult to interpret because the trial design de-
manded the stepwise reduction in IVIg dose after three months,
which might have confounded the comparison of improvement
in disability at later visits. Increasing scores on this scale indicate
worse disability. At 12 months, the score improved by at least one
point in one out of 13 mycophenolate mofetil and two out of 14
placebo participants, RR 0.54 (95% CI 0.06 to 5.26) in favour of
placebo (see Analysis 1.1 and Summary of findings for the main
comparison). The results at three and six months also showed no
statistically significant differences between treatment and control
groups.
The trial authors also measured disability with the Léger 2001 self
evaluation scale in which the participant scores their own ability
to perform five selected tasks appropriate to them on a scale from
zero = normal to five = impossible. At 12 months, the score im-
proved by at least one point in three of 14 placebo and none of 14
mycophenolate mofetil participants. The RR is impossible to de-
termine with zero responders in a group, but the risk of improve-
ment was not significantly different, being 21.43% (95%CI -0.07
to 42.92) lower (worse) in the mycophenolate mofetil group. The
results at three and six months were also not significant.
Secondary outcome measures
Significant improvement at least six months after
randomisation, on impairment scales
There were no significant differences in the MRC sum score or
nine-hole peg board time at baseline, 3, 6 or 12 months be-
tween themycophenolatemofetil and the placebo groups. After 12
months, there was a very small deterioration in themean (standard
deviation (SD)) MRC sum scores of both groups: -1.70 (5.91) in
the mycophenolate mofetil group and -1.66 (5.41) in the placebo
group without any significant difference between them: MD 0.04
(95% CI -4.46 to 4.54) more deterioration in the mycophenolate
mofetil group.
After 12 months, the mean right hand nine-hole peg test time
decreased (improved) slightly by -2.05 (7.17) seconds in 13 my-
cophenolate mofetil participants and increased (worsened) slightly
by 0.51 (5.87) seconds in 14 placebo participants; the MD was
non-significantly less (faster, that is, better) in the mycophenolate
mofetil group, -2.56 seconds (95% CI -12.58 to 7.46).
There were also no significant differences in the left hand nine-hole
peg test time at 12 months or in any of these outcome measures
at three and six months.
Requirement for IVIg treatment before and after at least six
months of treatment with immunosuppressive agents
There were no significant differences in the IVIg dose after six
or 12 months, the primary outcome measure selected by the trial
authors. We calculated the mean change in IVIg dose from base-
line which was 2.48 (8.67) g in the mycophenolate mofetil group
compared with 4.02 (10.44) g in the placebo group. The MD,
1.54 g (95% CI -9.18 g to 6.10 g) less in the mycophenolate
mofetil group, was not significant.
Improvement in motor conduction block after at least six
months
This outcome was not reported.
Serious adverse events
There were no serious adverse events in the trial. Mycopheno-
late mofetil was well tolerated. The only minor side-effect, which
was significantly more common in the mycophenolate mofetil
group, was headache. It occurred in seven out of 14 mycopheno-
late mofetil participants and only in one out of 14 placebo par-
ticipants (see Summary of findings for the main comparison), so
that the risk of headache was almost significantly higher with my-
cophenolate mofetil, RR 7.00 (95% CI 0.99 to 49.69).
Other measures reported by the trial authors.
Antibody titres of IgM antibodies to ganglioside GM1 did not
change significantly after one year of treatment.
D I S C U S S I O N
Introduction
Because of the expense, inconvenience and only partial response
of multifocal motor neuropathy (MMN) to intravenous im-
munoglobulin (IVIg) explained in the Background, there had been
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several case reports and series on the use of immunosuppressive
treatments such as cyclophosphamide when we first published this
review in 2002 and revised it in 2004. For the update in 2008,
one randomised controlled trial (RCT) had been published and
this tested mycophenolate mofetil. In this Discussion we will first
consider this trial and the limited non-randomised evidence con-
cerningmycophenolate mofetil and then consider in turn the non-
randomised evidence concerning other agents. In the 2014 up-
date we did not discover any new trials but updated the review of
non-randomised studies. It is not possible to identify all non-ran-
domised studies in this rare and recently described condition, but
as four neurologists with extensive experience of this disease we
expect to have included at least all consecutive series of more than
10 people with MMN. If readers know of other series of at least
this size, we would be pleased to be informed. We have presented
primary and second-line or adjunctive treatments separately.
Mycophenolate mofetil
The single small trial identified showed no benefit either in terms
of improvement in functional scales, which was the primary out-
come pre-selected for this review, or in reduction of IVIg require-
ment, the primary outcome selected by the trial authors. The
question arises whether this negative trial had adequate power to
rule out a clinically important effect of mycophenolate mofetil in
this disease. The primary outcome for this review could only be
measured after three months which would be enough to detect
changes following improvement in conduction block but not to
detect the effects on axonal regeneration. The careful follow-up
observations over the full 12-month period did not indicate signif-
icant improvement. Furthermore, as the trial authors discuss, the
beneficial effects of IVIg in other autoimmune disorders are seen
at a median period of 11 weeks. Nevertheless, if one accepts that
detecting 10% of responders in the treatment group compared
to zero responders in the placebo group would be worthwhile,
then with a five per cent level of significance and 80% power, a
trial would require 117 in each group or 234 in total (assuming
equal numbers in each group) without any allowance for dropouts.
These are much larger numbers than have so far been achieved in
MMN trials.
There is only limited evidence in the non-randomised literature
concerning mycophenolate mofetil. One person with MMN re-
fractory to other treatments did not respond to 1000 mg my-
cophenolate mofetil given twice a day for five months (Umapathi
2002). Benedetti 2004 administered 1 g of mycophenolate mofetil
twice a day to four people with MMN who were receiving regular
IVIg for six to 12 months. After four months, two individuals, one
of whom was also on cyclophosphamide, could stop IVIg. One
person could reduce the IVIg infusion by 50% after four months.
Another, whowas also on azathioprine, could reduce the IVIg dose
by 25% but only for four months. However, both of the people
on cyclophosphamide and azathioprine could discontinue these
drugs after about three months of mycophenolate-IVIg combina-
tion treatment. Unfortunately, two of the four people with MMN
treated eventually had to discontinue mycophenolate mofetil be-
cause of weight loss, anorexia, abdominal pain and raised serum
amylase. This limited evidence is trivial compared with the results
of Piepers 2007. It does, however, keep alive the possibility that
there are a small number of people who, like one in the Piepers
2007 trial, become able to reduce or stop IVIg. As argued in the
previous paragraph, It would take a much larger trial to discover
whether mycophenolate mofetil has this effect in, say, 10% of peo-
ple with MMN.
Immunosuppressive agents as primary therapy
for multifocal motor neuropathy
Cyclophosphamide
Primary treatment of MMN with immunosuppressive agents was
first explored in reports that appeared in the late 1980s, when the
entity of MMN was being recognised. Pestronk 1988 reported
that intravenous cyclophosphamide (3 g/m2) followed by oral cy-
clophosphamide produced marked improvement of limb strength
in two people after prednisone 100 mg daily for four to six months
and plasma exchange had failed. Intravenous cyclophosphamide
decreased the white blood cell counts of both the individuals
treated to below 2000/µl. Two years later Pestronk 1990 reported
the efficacy of cyclophosphamide in five people with MMN.
Subsequently an open label-study by Feldman et al. supported
the efficacy of cyclophosphamide as primary treatment in MMN
(Feldman 1991). The 13 participants in this study had had symp-
toms for between one and 20 years. Nine participants were treated
with intravenous cyclophosphamide (3 g/m2) followed by oral cy-
clophosphamide (2 mg/kg/day). Eight showed clinical improve-
ment of at least one Medical Research Council (MRC) grade dur-
ing the first two to five months of treatment. Of note, three re-
lapsed three to six months after stopping treatment. The side ef-
fects reported were alopecia and mild leucopenia. All participants
had previously been treated with high-dose prednisone without
clinical response. Four showed no improvement with plasma ex-
change.
Tan 1994 conducted a prospective, uncontrolled treatment trial
using cyclophosphamide and prednisolone on participants with
various forms of motor neuropathy. Eight participants who had a
lower motor neuron syndrome associated with partial conduction
block (more than 20% drop in amplitude and area of compound
muscle action potential) received intravenous cyclophosphamide
(3 g/m2) followed amonth later by oral cyclophosphamide (2 mg/
kg/day for six months). Five participants had a response, defined
as improvement of their average muscle score (derived from the
assessment of 28 muscle groups, graded according to an expanded
10-point scale) by more than 0.3 units. Six of these participants
had not responded in the first phase of the study, in which they had
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received four days of intravenous methylprednisolone followed by
100 mg of prednisolone every other day. Overall, only one partic-
ipant out of eight with lower motor neuron weakness and partial
conduction block responded to corticosteroids in the first phase.
Side effects reported among all the 45 participants treated with
cyclophosphamide in this trial (which consisted of participants
with various upper and lower motor neuron syndromes) included
haematuria, leucopenia, persistent diarrhoea and one participant
with pneumonia.
In a series of nine people with MMN (Chaudhry 1993), cyclo-
phosphamide improved strength in all three people treated with
this drug. Prednisone did not improve any of six people with
MMN and plasma exchange did not help either of two. Inter-
estingly, the three people initially treated with cyclophosphamide
were later noted to experience greater improvement of strength
with IVIg treatment. One person, who received a cumulative
dose of 90 g cyclophosphamide, developed acute myelogenous
leukaemia and died from complications of bone marrow trans-
plantation (Chaudhry 1996).
One person in Kaji 1993, a report on the pathology of nerves af-
fected in MMN, improved on 100 mg/day of cyclophosphamide
for 10 months. A year earlier, the same group reported a person
with MMN who did not respond to the same dose of cyclophos-
phamide. However, it was given for only one month and was com-
bined with corticosteroids and plasma exchange (Kaji 1992). In
a report of two people with MMN (Donaghy 1994), both im-
proved when treatment was switched to cyclophosphamide 100
mg day from corticosteroids but one subsequently developed lis-
teria meningitis and died from overwhelming abdominal sepsis.
Another person improved on oral cyclophosphamide (2 mg/kg/
day) after an unsatisfactory response to high doses of corticos-
teroids (oral prednisolone and intravenous methylprednisolone)
combined with plasma exchange and azathioprine (150 mg/day)
(Pringle 1997).
The efficacy of cyclophosphamide was mixed in another report
of three people with MMN (Krarup 1990): one responded to in-
travenous cyclophosphamide (total 3 g/m2), followed by oral cy-
clophosphamide (50 mg/day to 150 mg/day), while one did not
respond to a six-month regimen of oral cyclophosphamide (150
mg/day). Prednisolone was ineffective in all. In a series of five peo-
ple with MMN, none responded to cyclophosphamide, steroids
or plasma exchange, but all responded to IVIg (Comi 1994). In
another series of five people with MMN, two not improving or
stabilizing after a regimen of IVIg followed by azathioprine and
prednisolone slightly improved or stabilized after nine months of
intravenous cyclophosphamide at a dose of 1 g/m2 and 700 mg/
m2 (Ronquillo 2001).
Pestronk 2002 expressed the opinion, on theWashington Univer-
sity at St Louis Neuromuscular Diseases website, that six-monthly
treatment with 1 g/m2 of cyclophosphamide, each preceded by
two plasma exchanges could induce long-term improvement (and
reduction of GM1 antibodies) and is associated with fewer adverse
events than cyclophosphamide at 3 g/m2.
Corticosteroids
In addition to the reports mentioned above (Chaudhry 1993;
Comi 1994; Feldman 1991; Krarup 1990; Pestronk 1988; Pringle
1997; Tan 1994), a number of authors have highlighted the lack of
efficacy of corticosteroids in MMN. Pestronk 1990 reported that
out of seven people, only one improved on high-dose corticos-
teroids (details of the treatment regimen were not given). We have
listed other case reports on the lack of efficacy of corticosteroids
in MMN in Table 1. A number of reports have highlighted the
possible deleterious effect of corticosteroids in MMN (see Table
2). However, a few reports have suggested a possible benefit of
corticosteroid therapy for MMN (see Table 3).
Plasma exchange
Various reports and anecdotal experience have suggested that un-
like in chronic inflammatory demyelinating polyradiculoneuropa-
thy, plasma exchange may not be efficacious in MMN (Chaudhry
1993; Pestronk 1988; Pringle 1997; Vrethem 1996). One per-
son, described by Beydoun 1998, showed modest improvement
after six courses of plasma exchange. This response apparently
waned. However, there was prompt and marked improvement in
strength after a course of IVIg. This was sustained on monthly
IVIg infusions. In the series reported in Krarup 1990, of the two
people treated with plasma exchange, only one showed a mild
effect. Carpo 1998 reported an individual with motor neuropa-
thy who worsened clinically and on electrophysiological parame-
ters after plasma exchange. Conduction block developed in pre-
viously unaffected nerves. The person then improved after IVIg
infusion. A similar case of a person with MMN who deteriorated
after plasma exchange and subsequently improved on reinstating
IVIg was reported in Claus 2000. Beydoun 2000 reported a per-
son with MMN who presented with bilateral phrenic neuropathy
whose respiratory function improved significantly with 14 plasma
exchanges in three months. Subsequent limb weakness was suc-
cessfully treated with IVIg.
Seven cycles of immunoabsorption over 97 days were ineffective
in the person with MMN whose case was reported by Finsterer
1999a. In the largest retrospective series (Lehmann 2008), there
was no electrophysiological improvement and only two of seven
people treated improved clinically after PE (four to 18 treatments).
Cerebrospinal fluid filtration was also reported to be ineffective in
a person who had a good response to IVIg (Finsterer 1999).
Interferon beta
Three people with disease duration of seven to nine years resistant
to other treatments were given interferon beta-1a, six million in-
ternational units subcutaneously three times a week for six months
(Martina 1999). All improved clinically in the first three months
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of therapy and remained stable during the period of follow-up.
However, improvement on the Rankin scale was only documented
in one participant. The recorded side effects were flu-like symp-
toms, fever, sweating and erythema at injection sites. In a study of
interferon beta-1a in nine people (van den Berg-Vos 2000b), four
had received only one course of IVIg while the rest were on regular
infusions before the start of interferon beta-1a. Three participants
responded, apparently better than to IVIg. Six did not respond, of
whom four deteriorated. Interestingly five of the six non-respon-
ders were on maintenance IVIg prior to start of the trial. Four of
these participants received additional IVIg during the trial. The
authors speculated that IVIgmight have interfered with the action
of interferon beta-1a. The non-responders could also have been
advanced cases and therefore less likely to respond. However, the
people who responded to interferon in the Martina 1999 report
were chronic cases who had failed other therapy. Interferon shares
the low toxicity profile of IVIg and is easier to administer. How-
ever, the cost with prolonged use is also high.
Ciclosporin
Two people, one with a 12-year and one with a two-year history
responded within twomonths to ciclosporin 5mg/kg/day (Nemni
2003). In the second case the drug was discontinued after one year
and the person continued to be in remission for 39 months. The
authors felt that the immunophilin-ligand effect as well as the im-
munosuppressive effect of ciclosporin may have been responsible
for its efficacy.
Azathioprine
Hausmanowa-Petrusewicz 1991 described a individual with
MMN who did not respond to initial treatment with oral steroid
but started to improve 12 months after starting azathioprine 100
mg per day (it was unclear whether the individual was continuing
steroids). Bouche 1995 reported that azathioprine stabilised one
of the two people not responsive to IVIg. The single individual
with MMN in Krarup 1990 who was treated with azathioprine
200 mg /day did not improve.
Rituximab
Rituximab is a monoclonal antibody directed against the B cell
surface marker CD20. In a study of this drug in 21 people suffer-
ing from various polyneuropathies, 14 had MMN, of whom nine
had raised IgMGM1 antibody levels (Pestronk 2003). Themajor-
ity had stopped or never did respond to IVIg. The treatment con-
sisted of four intravenous weekly infusions of rituximab, 375 mg/
m2. Eight to 15 months later, about two-thirds of the participants
received repeat doses of rituximab, initially two-weekly and then
once every ten weeks. The response was compared with a non-
contemporaneous cohort of 13 participants, eight of whom had
MMN. At two years, the participants’ strength increased by about
a fifth while no significant change was noted in the comparison
group. The treatment was well tolerated. Light headedness, chills
and hypotension associated with the infusion improved after slow-
ing the rate of administration. Stieglbauer 2009 reported three
people with MMN, who had become increasingly less respon-
sive to IVIg but showed clinical improvement following rituximab
monotherapy. Michaud 2011 reported one person in whom the
addition of rituximab to IVIg appeared to cause improvement in
strength and disability for at least three years, although cyclophos-
phamide, azathioprine and mycophenolate had not been effective.
However, not all the reports have been favourable. In one single
case report, a person who had previously received IVIg, a similar
regimen was followed after two months by worsening and no re-
duction of IgM GM1 titres (Rojas-Garcia 2003).
Infliximab
A number of cases of peripheral neuropathy associated with
the use of tumour necrosis factor alpha (TNF-alpha) blocking
therapy, particularly infliximab, have been reported. Some of
these people have features of MMN (Cocito 2005; Fardet 2007;
Rodriguez-Escalera 2005; Singer 2004; Tektonidou 2007), al-
though cases of multi-focal chronic inflammatory demyelinating
polyneuroradiculopathy (Richez 2005),Guillain-Barré syndrome-
like illness (Cisternas 2002), vasculitic multiple mononeuropa-
thy (Jarrett 2003; Richette 2004) and subacute sensorimotor neu-
ropathy (Tektonidou 2007) have also been described. The lag-
time between therapy and the development of neuropathy varies
from three to 24 months (Rodriguez-Escalera 2005; Singer 2004;
Tektonidou 2007). Spontaneous recovery is observed with with-
drawal of infliximab in some people with MMN (Singer 2004;
Richez 2005). Others require immunosuppressive treatment (
Kosa 2009; Lozeron 2009; Tektonidou 2007). An increase of
serum TNF-alpha level in people with MMN after IVIg infusion
and in parallel with clinical improvement has also been reported
(Terenghi 2006). The role of TNF in MMN and the reason for
the possible induction ofMMNby antibodies to it are not known.
Nevertheless, with the present experience, it would be prudent not
to attempt treating MMN with TNF-blocking agents.
Summary of the evidence for immunosuppressive and
immunomodulatory agents as treatment for
multifocal motor neuropathy
In summary, the available non-randomised evidence suggests a
possible therapeutic role of cyclophosphamide in the primary
treatment of MMN, provided it is given at an adequate dose. Its
efficacy perhaps may even be comparable to IVIg. However, even
the small number of people with MMN reported to date con-
firm the experience from treatment of other diseases that cyclo-
phosphamide has significant adverse effects, some of which are
delayed by a number of years. Unfortunately there are insufficient
data on the effect of less toxic cytotoxic agents such as ciclosporin
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and azathioprine in the primary treatment of MMN. Similarly,
the efficacy of immunosuppressants such as rituximab and my-
cophenolate mofetil as primary or lone treatment of MMN is un-
clear. Corticosteroids and plasma exchange are probably ineffec-
tive. There are somany reports of corticosteroidsworseningMMN
as to discourage investigation of its therapeutic role. There is also
suggestion that plasma exchange may occasionally actually worsen
MMN. Interferon beta-1a is a relatively safe, albeit expensive al-
ternative which might be worth further investigation.
Immunosuppressive agents as adjunctive
treatment
The demonstrable efficacy of IVIg in MMN has prompted some
authors to start treatment with IVIg, and then add an immuno-
suppressive agent to reduce the need for frequent IVIg infusions
or to improve the clinical response. Younger age of onset (van den
Berg-Vos 2000c), fewer affected limbs (van den Berg-Vos 2000c),
creatine kinase level less than 180 U/L (van den Berg-Vos 2000c),
elevated anti-GM1antibody titres (Azulay 1997; vandenBerg-Vos
2000c), definite evidence of conduction block (van den Berg-Vos
2000c) and lack of amyotrophy (Bouche 1995) have been sug-
gested as factors that predict a good response to IVIg. More inten-
sive therapy with IVIg may also prevent long-term neurological
deterioration (Vucic 2004). Such prognostic factors, if they were
well validated, might help select people with MMN who may not
respond to IVIg alone and therefore benefit from the early intro-
duction of another therapeutic modality. The RCT included in
this review (Piepers 2007), did not demonstrate an adjunctive ef-
fect of mycophenolate mofetil when used with IVIg.
What is then the available evidence from uncontrolled studies for
immunosuppressants as adjuncts in the treatment of MMN?
Cyclophosphamide
In an open label trial of six participants treated with IVIg and cy-
clophosphamide (Meucci 1997), all responded to an initial course
of IVIg and were maintained on periodic infusions. Oral cyclo-
phosphamide was started at 1.5 mg/kg to 2 mg/kg and then sub-
sequently adjusted (0.5 mg/kg to 3 mg/kg) to maintain the white
cell count between 3000/µl to 3500/µl. The follow-up period was
37 to 61 (mean 47) months. After three to seven months of oral
cyclophosphamide, the interval between IVIg infusions could be
progressively increased until in three participants IVIg and cyclo-
phosphamide could be stopped after 13, 44 and 9 months. Two
years after cessation of treatment two participants worsened. The
third deteriorated 17 months after stopping treatment. Reinstate-
ment of periodic IVIg infusions induced clinical remission. Side
effects related to cyclophosphamide occurred. Two participants
had haemorrhagic cystitis, one after 13 and one after 15months of
treatment with a mean daily dose of 125 mg/day to 150 mg/day.
Their symptoms resolved on stopping the drug. Of these two par-
ticipants, one developed persistent amenorrhoea after one year of
treatment, while the other was found to have persistent azoosper-
mia a few years later (personal communication). The other par-
ticipants in this study, who needed a mean dose of only 25 mg to
90 mg a day of cyclophosphamide (the dose was not expressed in
relation to body weight) to induce the required level of leucope-
nia, did not experience any side effects during therapy. However,
one of them died of bladder carcinoma ten years after stopping
cyclophosphamide (personal communication).
Azulay et al. reported a series of 18 people with MMN followed
for a mean of 25.3 months who all received periodic IVIg (Azulay
1997). In six, treatment was deemed ineffective after three to
seven courses of IVIg. Three of these people received intravenous
cyclophosphamide (1 g/m2) monthly. This was subsequently re-
duced because of the development of leucopenia after two to three
months. Of these three people, one individual was assessed to have
improved after six months of treatment. Two other people in the
study received oral cyclophosphamide at 1 mg/kg to 1.5 mg/kg
and in one the frequency of IVIg could be reduced. The other
person stopped responding to IVIg after three doses and oral cy-
clophosphamide had apparently no effect on the clinical course.
Two important differences between theMeucci and Azulay studies
may explain the difference in response to cyclophosphamide. First,
in the Meucci study the cyclophosphamide dose was adjusted to
achieve a predetermined white cell count ensuring that adequate
immunosuppression was achieved. Second, in the Meucci study,
all the cases had responded to an initial course of IVIg. In Azu-
lay’s series, three of the five people with MMN who were given
cyclophosphamide had not responded to IVIg. However, Estrada-
Acosta et al. reported three people with MMN who responded to
intravenous cyclophosphamide followed by six months of oral cy-
clophosphamide, 100 mg/day, after not responding to IVIg, aza-
thioprine andprednisolone and, in one person, to plasma exchange
(Estrada-Acosta 1999), perhaps supporting the importance of ad-
equate dose rather than IVIg-responsiveness in determining effi-
cacy of cyclophosphamide.
In the retrospective series of 40 people with MMN, with a mean
follow-up of 2.2 +/-2.0 years, reported by Léger et al. (Léger
2008), eight people (22%) had significant remission (defined by
no current therapy for at least six months), whereas 25 (68%) were
dependent on periodic IVIg infusions, of whom eight were given
additional immunosuppressive agents, mainly cyclophosphamide
and azathioprine.
Terenghi et al. (Terenghi 2004) treated seven people with repeated
courses of IVIg and oral cyclophosphamide, one person receiv-
ing azathioprine and chlorambucil in addition. These individu-
als were followed for between five and 12 years. After a period of
good response, almost all those treated experienced a deterioration
in strength. This was most evident after six to eight years. This
clinical worsening was associated with reduction in mean distal
CMAP amplitude in examined nerves, suggesting that the treat-
ment regimen might not have been very effective in reducing ax-
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onal degeneration.
In a person with MMN who was refractory to IVIg, high dose cy-
clophosphamide, 50 mg/kg for four days without stem cell rescue
was able to induce remission. IVIg was discontinued and at six
months the individual’s strength improved and she regained the
ability to write (Brannagan 2006).
An adverse effect from cyclophosphamide followed by autologous
blood stem cell transplantation was reported in one person. He
had been dependent on IVIg every four weeks andwas treated with
high dose intravenous cyclophosphamide followed by autologous
blood stem cell transplantation. He deteriorated dramatically but
recovered when IVIg was re-instituted (Axelson 2008).
Rituximab
In a report of two people given intravenous rituximab 375 mg/m2
for four weeks, one achieved the primary end point of a reduction
in total IVIg dose by more than 25%, while in the other the
IVIg dose increased (Gorson 2007). In another report, one person,
who was becoming less responsive to IVIg and not responding
to or not tolerating adjunctive therapy with cyclophosphamide
and interferon beta-1a, annual courses of rituximab (375 mg/m
2 weekly for four weeks) for five years extended the interval of
IVIg administration from seven to 12 days. This corresponded to
a 42% reduction of IVIg (Ruegg 2004).
In an open label trial recently reported by Chaudhry 2011, six
people withMMNon periodic IVIg treatments received two doses
of rituximab 1000 mg two weeks apart. The amount of IVIg used
during the 12-month study period did not decrease when com-
pared to the previous 12 months. There was also no change in
MRC sum score, grip strength, overall disability sum score or the
Rotterdam handicap scale. Four people reported subjective im-
provement but oneworsened and one remained unchanged.Other
than one person who developed hypersensitivity, rituximab was
well tolerated.
Azathioprine
Oral azathioprine (150 mg/day for ten months then reduced to
100mg/day up to 14months) was reported to slightly delay disease
exacerbation and consequent IVIg infusion (Toscano 2002). In
Gutiérrez Ronquillo 2001, two out of five people with MMN
improved and one stabilized after a course of IVIg followed by
prednisone 60 mg/day for three months and azathioprine 50 mg/
day for 12 months.
Methotrexate
Eight people who had responded to IVIg and were clinically stable
on maintenance therapy received methotrexate (MTX) to reduce
IVIg dosage and improve strength (Nobile-Orazio 2009). MTX
was started at 7.5mg per week and increased to 10mg and then 15
mg at four weekly intervals. After four months of combined IVIg
and MTX treatment, the IVIg dose of those who were stable or
improving was reduced by 10% to 15% every two to three courses.
If there was clinical deterioration, the dose was reverted to the last
effective or starting dose. After a mean follow-up duration of 12.6
(range four to 18) months , three people continued MTX: one
could stop IVIg completely, one was able to reduce IVIg by 30%
and a third had subjective improvement (although disability scores
did not change significantly). Three people stoppedMTX because
of side effects (dyspnoea and gastrointestinal). One of these three
had a 50% reduction in IVIg dose while on treatment.
Interferon beta
Three people with MMN who had been receiving IVIg at inter-
vals of two to six weeks for an average of six years were given
subcutaneous interferon beta-1a 44 µg three times a week for six
months (Radziwill 2009). Two of them could increase the IVIg
infusion interval by two weeks. No change was seen in disability
scores, quality of life, electrophysiological parameters or cost. The
authors report that none of the individuals treated elected to con-
tinue treatment beyond the study period due to “mild side effects
and modest benefits”.
Eculizumab
Fitzpatrick at al. published an open label study of 13 people with
MMN using a monoclonal antibody, eculizumab, that prevents
cleavage of C5 and thus inhibits terminal complement activation
(Fitzpatrick 2011). Intravenous eculizumab 600 mg was given at
weeks zero, one, two and three, then 900 mg every two weeks
up to week 12 (five doses). Intravenous immunoglobulin was ad-
ministered regularly to 10 participants if they worsened to a pre-
determined deterioration point. The primary outcome was safety,
as assessed by the occurrence of adverse events during treatment
and compared to the run-in period. Secondary outcomes were
change in IVIg dosing frequency and change in multiple clinical
and functional efficacy measurements at 4, 8 and 14 weeks. Elec-
trophysiological parameters at baseline were compared with those
at week 14.
Eculizimab was generally well tolerated. The most common re-
ported adverse event was headache, occurring largely in the first
four weeks of treatment. Respiratory symptoms, musculoskeletal
complaints and rash occurred less frequently.Nopatient developed
a bacterial infection and none experienced worsening of MMN.
There was no change in dosing frequency in nine of the 10 par-
ticipants getting regular IVIg. One participant did not need IVIg
during the treatment period. There were no significant differences
in MRC sum score, but the sum of strength measured with a my-
ometer in five muscles improved significantly. A self rated func-
tional score improved significantly at week eight and 14 compared
to baseline. A significant but small (6.5%) decrease in conduction
block was detected.
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Although this study demonstrated the short-term safety of
eculizumab use with IVIg, evidence for efficacy was limited to
some of the efficacy outcome measures and there was no signifi-
cant reduction in requirement for IVIg. This result may have been
biased by the lack of randomisation and consequent absence of
blinding.
Comparison of non-randomised evidence
Overall, our non-systematic review of the various uncontrolled
studies on the adjunctive use of immunosuppressants for the treat-
ment of MMN suggests a moderate beneficial effect of cyclophos-
phamide. It may be more efficacious in participants who have re-
sponded to IVIg. A RCT would be needed to establish whether
the suggested benefit is real. Before such a trial were undertaken,
the known harms produced by cyclophosphamide would require
careful consideration. The use of corticosteroids, and occasionally
plasma exchange, has been associated with deterioration. The role
of less toxic cytotoxic agents, such as azathioprine, interferon beta,
ciclosporin, rituximab and methotrexate has not been adequately
explored.
Potential biases in the review process
MMN is a rare disease and the authors are likely to have known
about all randomised trials conducted or being conducted in the
field. The unavoidable weaknesses of the review are the dearth of
randomised trials and lack of large enough observational studies
to permit reliable conclusions. Even the one trial identified was
too small to identify or exclude even moderate benefit or harm.
General discussion
In conclusion, the data from a mixture of controlled trials, case
series and anecdotal experience have established IVIg as the first-
line treatment for MMN. A Cochrane systematic review agreed
with this conclusion (van Schaik 2005). One study that suggested
benefit from mycophenolate mofetil (Benedetti 2004) was not
supported by a subsequent RCT (Piepers 2007), which did not
show significant benefit in strength or function. The observational
data concerning other immunosuppressive agents have to be in-
terpreted with caution, because of publication bias and the wide
variability of clinical course and IVIg responsiveness of MMN
(Azulay 1997; Slee 2007; Taylor 2000; Terenghi 2004; van den
Berg 1998; Vucic 2004). The occurrence of MMN-like illness in
people taking infliximab, the worsening of some individuals while
on corticosteroids and our limited understanding of the patho-
genesis of MMN make it difficult to predict its response to novel
immunomodulatory agents. These factors magnify the need for
RCTs despite the logistical challenges.
Additional issues that need to be addressed in controlled studies
are:
(1) What is the best option for people with MMN who do not
respond to IVIg? A RCT of cyclophosphamide should be con-
sidered for severely affected people with MMN. The severity of
disability in such refractory cases may justify the use of a relatively
toxic medication such as cyclophosphamide. Less toxic drugs such
as azathioprine, ciclosporin, methotrexate or rituximab could be
studied in less severely affected individuals.
(2) For people withMMNwho lose their responsiveness or require
frequent IVIg infusions, the adjunctive therapeutic role of drugs
other than mycophenolate mofetil should be explored. Such treat-
ment regimens should be designed to reduce the slow neurological
deterioration that is seen in some people treated with regular IVIg
infusions (Taylor 2000; Terenghi 2004; van den Berg 1998; van
den Berg-Vos 2002).
(3) Studies to identify factors that predict lack or gradual loss of
response to IVIg (van den Berg-Vos 2000c; Vucic 2004) would
be useful in selecting people relatively early for alternative and
combination treatment regimens, before axonal damage precludes
significant recovery.
(4) More research is needed to identify the best outcomes to mea-
sure in multicentre trials of treatment for MMN. The self eval-
uation scale used in the Piepers 2007 trial has good face validity
but requires comparison with other scales and testing for repro-
ducibility and responsiveness. Other existing scales might be su-
perior but new more responsive scales might need to be developed
to increase the power of MMN treatment trials. The correlation
between resolution of conduction block and clinical response to
treatment has varied in different studies (Federico 2000; Léger
2001; Léger 2008). Alternative responsive electrodiagnostic out-
come measures would be helpful. An international workshop has
proposed a Rasch derived disability outcome scale as the preferred
primary outcome measure (Vanhoutte 2013). The workshop also
recommended aRasch transformedMRC scale, strengthmeasured
with a dynamometer (especially of muscle groups relevant to the
individual) and Rasch transformed Quality of Life scales as sec-
ondary outcome measures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
According tomoderate quality evidence from the only randomised
controlled trial of an immunosuppressive agent in multifocal mo-
tor neuropathy, mycophenolate mofetil did not significantly im-
prove strength or function or reduce the need for intravenous im-
munoglobulin.
Implications for research
Randomised controlled trials are needed of cyclophosphamide for
severe disease, and less toxic agents, other than mycophenolate
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mofetil, for moderate or mild disease, to reduce the need for intra-
venous immunoglobulin in people who respond to it and to treat
people who do not respond. The scales for measuring disability in
multifocal motor neuropathy need to be optimised.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Piepers 2007
Methods Double-blind, parallel-group, randomised trial
Participants 28 people with multifocal motor neuropathy at a single centre (Department of Neuro-
muscular Diseases, UMC Utrecht)
Male:female ratio, 13:1 and 11:3 (mycophenolate mofetil and placebo groups, respec-
tively); mean ages 50 (SD 8) and 49 (SD 8) years
Interventions Mycophenolate mofetil 1 g twice a day (n = 14) or placebo (n = 14) for 12 months
Outcomes Primary outcome: 50% or more reduction of baseline mean weekly IVIg dose
Secondary outcomes:
• Improvement of muscle strength at 3 months (combined MRC scale of 15
muscles on both sides)
• Improvement of functional status at 3 months using Guy’s Neurological
Disability Scale (Sharrack 1999), the self evaluation scale (Léger 2001) and the nine-
hole peg test (Oxford 2003; Sharrack 1999)
• Reduction of IgM GM1 antibody titre after 12 months
Funding “MMF [mycophenolate mofetil] was obtained from Roche Pharmaceuticals, and MMF
and placebo were packed in identical capsules. MMF was obtained free from Roche.
Roche pharmaceuticals was not involved in the study design and did not support the
performance of the trial. All patients received the same brand of immunoglobulins;
Gammagard (Baxter)”
Conflicts of interest Declaration of interest not provided
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to re-
ceive either mycophenolate mofetil (500
mg twice daily during the first week, 1000
mg twice daily thereafter) or placebo. “Ran-
domisation was performed by one of the
investigators (RB), using block randomi-
sation with stratification for the extent
of muscle weakness at baseline (treatment
group A: MRC sum score <95; treatment
group B: MRC sum score >95). After allo-
cating the participants to one of the treat-
ment groups, each participant was given
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Piepers 2007 (Continued)
a number (0 to 15 to participants allo-
cated to treatment group A, numbers 16
to 30 to participants allocated to treat-
ment group B). Randomisation numbers
were passed on to the research pharma-
cist, who had randomly assigned mycophe-
nolate mofetil/placebo to corresponding
numbers.Only the research pharmacist had
access to the trial codes. Trial medication
was packed in blank containers and handed
out to the participants. Neither investiga-
tors nor participants were aware of group
assignment until the end of the trial”. Ran-
domisation considered adequate
Allocation concealment (selection bias) Low risk Participants were randomly assigned to re-
ceive either mycophenolate mofetil (500
mg twice daily during the first week, 1000
mg twice daily thereafter) or placebo for
a period of 12 months. “Mycophenolate
mofetil was obtained from Roche Pharma-
ceuticals, and mycophenolate mofetil and
placebo were packed in identical capsules.
Mycophenolate mofetil was obtained free
from Roche. Roche pharmaceuticals was
not involved in the study design and did
not support the performance of the trial.
All participants received the same brand
of immunoglobulins; Gammagard (Baxter)
. Randomisation was performed by one
of the investigators (RB), using block ran-
domisation with stratification for the ex-
tent of muscle weakness at baseline (treat-
ment group A:MRC sum score < 95; treat-
ment group B: MRC sum score > 95). Af-
ter allocating the participants to one of
the treatment groups, each participant was
given a number (0 to 15 to participants
allocated to treatment group A, numbers
16 to 30 to participants allocated to treat-
ment group B). Randomisation numbers
were passed on to the research pharma-
cist, who had randomly assigned mycophe-
nolate mofetil/placebo to corresponding
numbers.Only the research pharmacist had
access to the trial codes. Trial medication
was packed in blank containers and handed
out to the participants. Neither investiga-
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Piepers 2007 (Continued)
tors nor participants were aware of group
assignment until the end of the trial.” Al-
location concealment considered adequate
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants were randomly assigned to re-
ceive either mycophenolate mofetil (500
mg twice daily during the first week, 1000
mg twice daily thereafter) or placebo for
a period of 12 months. Mycophenolate
mofetil was obtained from Roche Pharma-
ceuticals, and mycophenolate mofetil and
placebo were packed in identical capsules.
Mycophenolate mofetil was obtained free
from Roche. Roche pharmaceuticals was
not involved in the study design and did
not support the performance of the trial.
All patients received the same brand of
immunoglobulins; Gammagard (Baxter).
Randomisation was performed by one of
the investigators (RB), using block ran-
domisation with stratification for the ex-
tent of muscle weakness at baseline (treat-
ment group A:MRC sum score < 95; treat-
ment group B:MRC sum score > 95). After
allocating the patients to one of the treat-
ment groups, each participant was given
a number (0 to 15 to participants allo-
cated to treatment group A, numbers 16
to 30 to participants allocated to treat-
ment group B). Randomisation numbers
were passed on to the research pharma-
cist, who had randomly assigned mycophe-
nolate mofetil/placebo to corresponding
numbers.Only the research pharmacist had
access to the trial codes. Trial medication
was packed in blank containers and handed
out to the participants. Neither investiga-
tors nor participants were aware of group
assignment until the end of the trial. Blind-
ing considered adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one participant in each group was not
followed up and included in the analysis
(because of withdrawal of consent after 3
months). 1 participant each in treatment
and placebo group withdrew, for “flu-like”
symptoms and “unacceptable deterioration
in muscle strength” respectively. Analysis
was by “intention to treat”
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Piepers 2007 (Continued)
Selective reporting (reporting bias) Low risk There is no indication of selective reporting
in this study as all the outcomes decided
a priori were reported upon even though
none of them showed a positive outcome
Other bias Low risk “Neither investigators nor participants
were aware of group assignment until
the end of the trial”. Baseline character-
istics comparable between treatment and
placebo groups
IVIg: intravenous immunoglobulin; IgM: immunoglobulin M; MRC: Medical Research Council.
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D A T A A N D A N A L Y S E S
Comparison 1. Mycophenolate mofetil versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in GNDS after 12
months
1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.06, 5.26]
2 Serious adverse events 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Mycophenolate mofetil versus placebo, Outcome 1 Improvement in GNDS
after 12 months.
Review: Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy
Comparison: 1 Mycophenolate mofetil versus placebo
Outcome: 1 Improvement in GNDS after 12 months
Study or subgroup
Mycophenolate
mofetil Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Piepers 2007 1/13 2/14 100.0 % 0.54 [ 0.06, 5.26 ]
Total (95% CI) 13 14 100.0 % 0.54 [ 0.06, 5.26 ]
Total events: 1 (Mycophenolate mofetil), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours mycophenolate
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Analysis 1.2. Comparison 1 Mycophenolate mofetil versus placebo, Outcome 2 Serious adverse events.
Review: Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy
Comparison: 1 Mycophenolate mofetil versus placebo
Outcome: 2 Serious adverse events
Study or subgroup
Mycophenolate
mofetil Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Piepers 2007 0/14 0/14 Not estimable
Total (95% CI) 14 14 Not estimable
Total events: 0 (Mycophenolate mofetil), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours mycophenolate Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Reports of lack of response to corticosteroids
Krarup 1990 None of 3 people with MMN on oral prednisolone improved. 1 person became weaker on a dose
of 25 mg/day
Charles 1992 1 person responded to IVIg after not responding to prednisolone 60 mg/day for 2 months
Kaji 1992. 1 person with MMN received oral prednisolone 50 mg/day for 1 month followed by 200 mg/week
of intravenous methylprednisolone 2 days/week for two months, followed by twice weekly plasma
exchange for weeks, and oral cyclophosphamide 100 mg/day for one month. 1 person received
oral prednisolone 50 mg/day for three months. Neither improved but both responded to IVIg
Hausmanowa-Petrusewicz 1991 1 person with MMN did not respond to prednisone 80 mg/d but improved 12 months after
starting azathioprine 100 mg/day
Nobile-Orazio 1993 3 out of 5 people with MMN were treated with corticosteroids, with no effect in 2 and severe
deterioration in 1
Jaspert 1996 2 people with MMN received corticosteroid without adequate clinical response but responded to
IVIg
Abbruzzese 1997 1 person with MMN did not respond to prednisolone 50 mg/d for 4 weeks but responded to IVIg
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Table 1. Reports of lack of response to corticosteroids (Continued)
Azulay 1997 4 person with MMN received prednisolone 1 mg/kg/day without improvement
Table 2. Reports of worsening while on corticosteroids
Donaghy 1994 4 person with MMN showed significant motor deterioration within 4 weeks of starting prednisolone 60 mg/
day. In 2, stopping the treatment reversed this acute decline
Vrethem 1996 1 person with MMN did not respond to 8 plasma exchanges, possibly got worse on steroids; but improved
about one week after IVIg
van den Berg 1997 2 person with MMN deteriorated on high-dose dexamethasone. They subsequently improved on IVIg
Le Forestier 1997 2 person with MMN worsened on corticosteroids. Corticosteroid treatment precipitated worsening in 6 of 9
people. Two other people developedMMN only after the introduction of corticosteroids for another indication
Table 3. Reports of improvement of MMN while on corticosteroids.
Parry 1988 1 person with MMN on 60 mg of prednisolone a day followed
later by the addition of azathioprine 150 mg/day
de Carvalho 1997 1personwithMMNresponded to low-dose corticosteroids.How-
ever, this person had raised cerebrospinal fluid protein (100 mg/
dl)
Komiyama 1998 1 person with MMN responded to pulsed methylprednisolone
followed by maintenance prednisolone
Van den Bergh 1989 1 person with MMN improved gradually while on plasma ex-
change and long-term corticosteroid therapy
Bentes 1999 (this individual is the same reported by de Carvalho
1997)
1 out of 9 people with MMN responded to corticosteroids
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A P P E N D I C E S
Appendix 1. CRS search strategy
#1 “multifocal motor neuropath*” [REFERENCE] [STANDARD]
#2 “conduction block*” or “motor neuropath*” [REFERENCE] [STANDARD]
#3 #2 and multifocal [REFERENCE] [STANDARD]
#4 #1 or #3 [REFERENCE] [STANDARD]
#5 “immunosuppressive agent*” or “plasma exchange” or plasmapheresis [REFERENCE] [STANDARD]
#6 azathioprine or cyclophosphamide or cyclosporin* or ciclosporin* or methotrexate or rituximab or eculizumab or infliximab
[REFERENCE] [STANDARD]
#7 MeSH DESCRIPTOR Adjuvants, Immunologic [REFERENCE] [STANDARD]
#8 adjuvants NEAR immunologic [REFERENCE] [STANDARD]
#9 immunomodulat* or interferon* or immunosuppress* mycophenolate or mycophenolic [REFERENCE] [STANDARD]
#10 MeSH DESCRIPTOR Interferons Explode All [REFERENCE] [STANDARD]
#11 irradiation NEAR lymph* [REFERENCE] [STANDARD]
#12 “bone marrow transplant*” [REFERENCE] [STANDARD]
#13 MeSH DESCRIPTOR Antibodies, Monoclonal Explode All [REFERENCE] [STANDARD]
#14 monoclonal NEAR1 antibod* [REFERENCE] [STANDARD]
#15 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All [REFERENCE] [STANDARD]
#16 (subcutaneous NEAR4 immunoglobulin*) or scig [REFERENCE] [STANDARD]
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 [REFERENCE] [STANDARD]
#18 #4 and #17 [REFERENCE] [STANDARD]
#19 (#4 and #17) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. CENTRAL search strategy
#1 “multifocal motor neuropathy” or “multifocal motor neuropathies”
#2 “conduction block” or “conduction blocks” or “motor neuropathy” or “motor neuropathies”
#3 #2 and multifocal
#4 #1 or #3
#5 MeSH descriptor: [Immunosuppressive Agents] explode all trees
#6 “immunosuppressive agent” or “plasma exchange” or plasmapheresis or azathioprine or cyclophosphamide or cyclosporin or cy-
closporine or ciclosporine
#7 methotrexate or rituximab or immunomodulat* or interferon*
#8 MeSH descriptor: [Adjuvants, Immunologic] this term only
#9 MeSH descriptor: [Interferons] explode all trees
#10 “lymphatic irradiation” or immunosuppressant* “mycophenolic acid”
#11 “bone marrow” near transplant*
#12 MeSH descriptor: [Antibodies, Monoclonal] explode all trees
#13 monoclonal near/1 antibod*
#14 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#15 subcutaneous near/4 immunoglobulin*
#16 scig
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
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Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to September Week 2 2014>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (388375)
2 controlled clinical trial.pt. (89809)
3 randomized.ab. (284414)
4 placebo.ab. (150745)
5 drug therapy.fs. (1744932)
6 randomly.ab. (201022)
7 trial.ab. (295504)
8 groups.ab. (1282228)
9 or/1-8 (3283677)
10 exp animals/ not humans.sh. (4011372)
11 9 not 10 (2797292)
12 multifocal motor neuropath$.mp. (565)
13 conduction block$.mp. (3256)
14 motor neuropathy.mp. (2381)
15 (13 or 14) and multifocal.mp. (712)
16 12 or 15 (716)
17 (myeloma or lymphoma).sh. (44914)
18 16 not 17 (715)
19 immunosuppressive agent$.tw. (7960)
20 Immunosuppressive agents/ (77318)
21 plasma exchange.tw. or Plasma exchange/ (7137)
22 Azathioprine.tw. or AZATHIOPRINE/ (19232)
23 cyclophosphamide.tw. or CYCLOPHOSPHAMIDE/ (58019)
24 cyclosporin$.tw. or Cyclosporine/ or ciclosporin$.tw. (48990)
25 methotrexate.tw. or METHOTREXATE/ (41995)
26 rituximab.mp. (11689)
27 ADJUVANTS, IMMUNOLOGIC/ (32021)
28 immunomodulat$.tw. (33892)
29 interferon.mp. or exp Interferons/ (154666)
30 Lymphatic Irradiation/ (1006)
31 lymph$ irradiation.tw. (795)
32 bone marrow transplantation.tw. or Bone Marrow Transplantation/ (47705)
33 immunosuppressant$.mp. (10074)
34 mycophenolate.mp. (8425)
35 Mycophenolic Acid/ (6277)
36 exp monoclonal antibodies/ (183667)
37 (monoclonal adj1 antibod$).tw. (156804)
38 exp adrenal cortex hormones/ (341273)
39 ((subcutaneous adj4 immunoglobulin$) or scig).mp. (202)
40 (eculizumab or infliximab).mp. (9415)
41 or/19-40 (960869)
42 11 and 18 and 41 (112)
43 remove duplicates from 42 (107)
44 case reports.pt. (1713335)
45 43 not 44 (73)
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Appendix 4. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2014 Week 38>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (40222)
2 double-blind procedure.sh. (115438)
3 single-blind procedure.sh. (18827)
4 randomized controlled trial.sh. (350056)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1060969)
6 trial.ti. (162680)
7 or/1-6 (1194282)
8 exp animal/ or exp invertebrate/ or animal.hw. or non human/ or nonhuman/ (20191835)
9 human/ or human cell/ or human tissue/ or normal human/ (15057329)
10 8 not 9 (5167170)
11 7 not 10 (1047318)
12 limit 11 to embase (860567)
13 multifocal motor neuropath$.tw. (862)
14 (conduction block$ or motor neuropath$).mp. (8182)
15 14 and multifocal.mp. (1191)
16 13 or 15 (1191)
17 (myeloma or lymphoma).sh. (81376)
18 16 not 17 (1163)
19 exp Immunosuppressive Agent/ (548291)
20 immunosuppressive agent$1.tw. (10370)
21 plasma exchange.mp. or Plasmapheresis/ (28088)
22 AZATHIOPRINE/ or Azathioprine.mp. (72896)
23 CYCLOPHOSPHAMIDE/ or cyclophosphamide.mp. (165183)
24 CYCLOSPORIN/ or cyclosporin.mp. (126781)
25 methotrexate.mp. or METHOTREXATE/ (130384)
26 rituximab.mp. or RITUXIMAB/ (41757)
27 exp Immunological Adjuvant/ (24448)
28 (immunologic adj1 adjuvant$1).mp. (183)
29 immunomodulation/ (54837)
30 immunomodulat$3.tw. (48346)
31 exp interferon/ (349249)
32 interferon$1.tw. (140818)
33 exp radiotherapy/ (374992)
34 lymph$4 irradiation.tw. (929)
35 bone marrow transplantation.mp. or exp Bone Marrow Transplantation/ (59336)
36 exp monoclonal antibody/ (346492)
37 (monoclonal adj1 antibod$).mp. (247766)
38 exp corticosteroid/ (691505)
39 (subcutaneous adj4 immunoglobulin$).mp. (434)
40 scig.mp. (318)
41 (eculizumab or infliximab).mp. (32518)
42 or/19-41 (2009227)
43 12 and 18 and 42 (58)
44 remove duplicates from 43 (58)
45 limit 44 to yr=“1986 -Current” (58)
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Appendix 5. LILACS search strategy
(“multifocal motor neuropathy” or “neuropatia motora multifocal” or ((“conduction block” or “conduction blocks” or “bloqueio de
conducao” or “bloqueios de conducao” or “blanqueos de conduccion” or “motor neuropathy”) and multifocal)) and (((PT:“Random-
ized Controlled Trial” or “Randomized Controlled trial” or “Ensayo Clínico Controlado Aleatorio” or “Ensaio Clínico Controlado
Aleatório” or PT:“Controlled Clinical Trial” or “Ensayo Clínico Controlado” or “Ensaio Clínico Controlado” or “Random allocation”
or “Distribución Aleatoria” or “Distribuição Aleatória” or randon$ or Randomized or randomly or “double blind” or “duplo-cego” or
“duplo-cego” or “single blind” or “simples-cego” or “simples cego” or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT
(humans or humanos or humanos))))
WH A T ’ S N E W
Last assessed as up-to-date: 22 September 2014.
Date Event Description
22 December 2014 New citation required but conclusions have not
changed
New searches fully incorporated
22 September 2014 New search has been performed All search strategies were updated and made more spe-
cific for MMN
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 2, 2002
Date Event Description
17 January 2012 New citation required but conclusions have not
changed
New searches fully incorporated
2 August 2011 New search has been performed New searches were run but no new randomised con-
trolled trials identified. Updated non-randomised stud-
ies. ’Summary of findings’ and ’Risk of bias’ tables
added
8 October 2008 New search has been performed Updated in 2008 to incorporate one new randomised
trial
8 October 2008 New citation required and conclusions have changed Updated review to incorporate one new randomised
controlled trial
26 April 2008 Amended Converted to new review format.
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(Continued)
25 February 2005 New citation required and conclusions have changed Substantive amendment. We updated the search of the
Cochrane Neuromuscular Disease Group trials register
in February 2004, MEDLINE (January 1966 to end
May 2004) and EMBASE (January 1980 to end May
2004). No randomised or quasi-randomised trials that
met the selection criteria for the review were found.
Additional non-randomised studies have been added to
the Background and Discussion sections
C O N T R I B U T I O N S O F A U T H O R S
TU wrote the first draft. All the authors commented on this and subsequent drafts and agreed the final text.
D E C L A R A T I O N S O F I N T E R E S T
TU received honoraria for lecturing from Baxter and Menarini that were subsequently donated to charity.
RACH holds or has held consultancies with CSL Behring, Grifols and LFB which make intravenous immunoglobulin (IVIg) which is
used as the main treatment for multifocal motor neuropathy (MMN) and also with Novartis which is conducting a trial of fingolimod
in a related condition, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). He was the chief investigator of a trial
investigating the efficacy of methotrexate in CIDP.
EN-O is the principal investigator of two trials sponsored by LFB on the use of IVIg in CIDP. He was the principal investigator in
a randomised controlled trial (RCT) sponsored by Kedrion comparing the efficacy of intravenous steroids with IVIg in CIDP. He
participated as local principal investigator in a spontaneous RCT comparing methotrexate with placebo in CIDP. He has received
payment for service on the Scientific Advisory Board for Sponsored Meetings of Baxter Italy and CSL Behring Italy, on the scientific
advisory board ’Kedrion Global Immunoglobulin Advisory Panel’ for Kedrion Italy, and on the Steering Committee of a fingolimod
trial in CIDP for Novartis Switzerland. He has received honoraria for lecturing from Baxter Italy, CSL Behring Italy, Grifols Spain
and Kedrion Italy and travel support to attend Scientific Meetings from Kedrion Italy. He states that no part of the above mentioned
financial support had any influence on his work in preparing this review.
The institution of J-ML Léger has received grants from CSL Behring France, CSL Behring Germany, LFB and Octapharma France
(manufacturers of IVIg) for clinical trials; payment from CSL Behring France for membership of an advisory board; from LFB, CSL
Behring France and Octapharma France for data monitoring board membership; from CSL Behring France, CSL Behring Germany,
Baxter and Novartis for consultancy; from CSL Behring France, Spain and Germany, LFB, Baxter, Novartis, Biogen Idec and Kedrion
for lectures in symposia; and from CSL Behring France and LFB for development of educational presentations. J-ML has received
honoraria from LFB and Novartis France to attend American Academy of Neurology and Peripheral Nerve Society meetings. J-ML
was the chief investigator of a randomised trial of IVIg funded by Immuno-AG and then Baxter. He is also the chief investigator of
a retrospective study of the safety and efficacy of IVIg funded by Octapharma in multifocal motor neuropathy (not published yet);
was the chief investigator of a randomised, double-blind trial of rituximab (Roche) in anti-myelin-associated glycoprotein (anti-MAG)
neuropathy, and is the chief investigator of a single-arm study of IVIg funded by CSL Behring in CIDP.
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S O U R C E S O F S U P P O R T
Internal sources
• King’s College, London, UK.
External sources
• Donation from Mr and Mrs Chris Lazari, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
’Summary of findings’ and ’Risk of bias’ tables added.
At this update we activated subheadings and expanded the methods section to address current Cochrane standards. We specified that
there would be no language restrictions in the searches. We stated how we would have resolved any disagreements on study selection,
data extraction and ’Risk of bias’ assessment. We described how we would have assessed heterogeneity. We stated whether we would
use a fixed-effect or random-effects model if conducting a meta-analysis.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Drug Therapy, Combination [methods]; Immunoglobulins, Intravenous [∗therapeutic use]; Immunologic Factors [∗therapeutic use];
Immunosuppressive Agents [∗therapeutic use]; Motor Neuron Disease [∗drug therapy]; Mycophenolic Acid [∗analogs & derivatives;
therapeutic use]; Polyneuropathies [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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